Privately-held genome-scale drug discovery company Orionis Biosciences today revealed a multi-year collaboration with Genentech, the US biotech subsidiary of Swiss pharm giant Roche (ROG: SIX), to discover novel small molecule medicines for challenging targets in major disease areas, including oncology and neurodegeneration.
Orionis’ Allo-Glue platform utilizes multiple unique approaches to discover drug-like small molecules against disease targets that have remained elusive to traditional discovery approaches.
The accord provides for Orionis to be responsible for the discovery and optimization of molecular glues for Genentech’s designated targets, while Genentech will be responsible for subsequent later-stage pre-clinical, clinical development, regulatory filing, and commercialization of such small molecules.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze